SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

M V Karg; A Bosch; D Kannenkeril; K Striepe; Christian Ott; Markus Schneider; F Boemke-Zelch; P Linz; A M Nagel; J Titze; M Uder; R E Schmieder

doi:10.1186/s12933-017-0654-z

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

M V Karg, A Bosch, D Kannenkeril, K Striepe, Christian Ott (Co-Autor/-in), Markus Schneider (Co-Autor/-in), F Boemke-Zelch, P Linz, A M Nagel, J Titze, M Uder, R E Schmieder

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

157 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	5
Fachzeitschrift	CARDIOVASCULAR DIABETOLOGY
Jahrgang	17
Ausgabenummer	1
DOIs	https://doi.org/10.1186/s12933-017-0654-z
Publikationsstatus	Veröffentlicht - 2018

Zugriff auf Dokument

10.1186/s12933-017-0654-z

Dieses zitieren

@article{3d90b44ab5804628abed01bd63d9fb75,

title = "SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.",

keywords = "TYPE-2 DIABETES-MELLITUS, COTRANSPORTER 2 INHIBITORS, BLOOD-PRESSURE, GLYCEMIC CONTROL, NA+ STORAGE, HYPERTENSION, NA-23, SALT, SKIN, EMPAGLIFLOZIN",

author = "Karg, \{M V\} and A Bosch and D Kannenkeril and K Striepe and Christian Ott and Markus Schneider and F Boemke-Zelch and P Linz and Nagel, \{A M\} and J Titze and M Uder and Schmieder, \{R E\}",

note = "Ott, C; Schneider, MP: Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany. ",

year = "2018",

doi = "10.1186/s12933-017-0654-z",

language = "English",

volume = "17",

pages = "5",

journal = "CARDIOVASCULAR DIABETOLOGY",

issn = "1475-2840",

publisher = " BioMed Central",

number = "1",

}

TY - JOUR

T1 - SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

AU - Karg, M V

AU - Bosch, A

AU - Kannenkeril, D

AU - Striepe, K

AU - Ott, Christian

AU - Schneider, Markus

AU - Boemke-Zelch, F

AU - Linz, P

AU - Nagel, A M

AU - Titze, J

AU - Uder, M

AU - Schmieder, R E

N1 - Ott, C; Schneider, MP: Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany.

PY - 2018

Y1 - 2018

KW - TYPE-2 DIABETES-MELLITUS

KW - COTRANSPORTER 2 INHIBITORS

KW - BLOOD-PRESSURE

KW - GLYCEMIC CONTROL

KW - NA+ STORAGE

KW - HYPERTENSION

KW - NA-23

KW - SALT

KW - SKIN

KW - EMPAGLIFLOZIN

U2 - 10.1186/s12933-017-0654-z

DO - 10.1186/s12933-017-0654-z

M3 - Original Article

C2 - 29301520

SN - 1475-2840

VL - 17

SP - 5

JO - CARDIOVASCULAR DIABETOLOGY

JF - CARDIOVASCULAR DIABETOLOGY

IS - 1

ER -